EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director.
Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd.
Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NASDAQ in 2019. He joined Bicycle from Pfizer, where he served as senior vice president and CSO of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer's rare disease strategy, conceptualized and implemented the company's gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded ...